| Analysis of factors predicting survival in patients with hepatocellular carcinoma treated with percutaneous laser ablation. | |
| | |
MedLine Citation:
|
PMID: 16545480 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND/AIMS: The factors which predict the long-term outcome in patients with hepatocellular carcinoma who are treated with percutaneous laser ablation (PLA) are not well established. METHODS: We prospectively analyzed treatment and survival parameters of 148 cirrhotic patients with nonsurgical hepatocellular carcinoma who had undergone PLA at a single institution during an 11-year period. RESULTS: Single tumors were seen in 129 of 148 (87%) patients, and 2-3 nodules were seen in 19 (13%) patients, for a total of 169 tumors. The median overall time survival was 39 months (95% confidence interval [CI], 30-47 months). The 1-, 2-, 3-, 4-, and 5-year cumulative survival rates were 89, 75, 52, 43, and 27%, respectively. From multiple regression analysis, the independent predictors of survival were found to be tumor grading (P=0.002; risk ratio [RR] 0.37, 95% CI 0.20-0.70), bilirubin levels < or =2.5mg/dl (P=0.014; RR 1.58, 95% CI 1.09-2.28), and the achievement of complete tumor ablation (P=0.020; RR 0.53, 95% CI 0.31-0.90). An initial complete tumor ablation was the only factor associated with longer survival in patients with Child-Turcotte-Pugh class A cirrhosis (P=0.012; hazard ratio [HR] 0.48, 95% CI 0.23-1.03). CONCLUSIONS: A complete tumor ablation results in improved survival in all patients with nonsurgical hepatocellular carcinoma. Ideal candidates for PLA are those with a well-differentiated histology, and normal bilirubin levels. |
| | |
Authors:
|
Claudio Maurizio Pacella; Giancarlo Bizzarri; Giampiero Francica; Giuseppe Forlini; Alessandra Petrolati; Dario Valle; Vincenzo Anelli; Antonio Bianchini; Stefano De Nuntis; Sara Pacella; Zaccaria Rossi; John Osborn; Roberto Stasi |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't Date: 2006-02-28 |
Journal Detail:
|
Title: Journal of hepatology Volume: 44 ISSN: 0168-8278 ISO Abbreviation: J. Hepatol. Publication Date: 2006 May |
Date Detail:
|
Created Date: 2006-04-17 Completed Date: 2006-09-27 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8503886 Medline TA: J Hepatol Country: England |
Other Details:
|
Languages: eng Pagination: 902-9 Citation Subset: IM |
Affiliation:
|
Department of Diagnostic Imaging and Interventional Radiology, Ospedale Regina Apostolorum, Via San Francesco, 50-00041, Albano Laziale, Rome, Italy. cmpacel@katamail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Bilirubin / blood Carcinoma, Hepatocellular / mortality*, pathology, surgery* Female Follow-Up Studies Humans Laser Therapy* Liver Neoplasms / mortality*, pathology, surgery* Male Middle Aged Necrosis Postoperative Complications / mortality Predictive Value of Tests Prospective Studies Regression Analysis Survival Analysis Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
635-65-4/Bilirubin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Controlled release of plasmid DNA from hydrogels prepared from gelatin cationized by different amine...
Next Document: Increased phosphodiesterase-5 expression is involved in the decreased vasodilator response to nitric...